| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SPRY4 |
| Uniprot No | Q9C004 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-299aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMEPPIPQ SAPLTPNSVM VQPLLDSRMS HSRLQHPLTI LPIDQVKTSH VENDYIDNPS LALTTGPKRT RGGAPELAPT PARCDQDVTH HWISFSGRPS SVSSSSSTSS DQRLLDHMAP PPVADQASPR AVRIQPKVVH CQPLDLKGPA VPPELDKHFL LCEACGKCKC KECASPRTLP SCWVCNQECL CSAQTLVNYG TCMCLVQGIF YHCTNEDDEG SCADHPCSCS RSNCCARWSF MGALSVVLPC LLCYLPATGC VKLAQRGYDR LRRPGCRCKH TNSVICKAAS GDAKTSRPDK PF |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SPRY4重组蛋白的3篇参考文献示例(虚拟文献，供参考格式)：
1. **标题**：SPRY4 Recombinant Protein Suppresses Tumor Growth by Inhibiting MAPK Signaling
**作者**：Li X, et al.
**摘要**：该研究通过大肠杆菌表达纯化人源SPRY4重组蛋白，发现其能通过结合RAS蛋白抑制MAPK信号通路，在体外和小鼠模型中显著抑制黑色素瘤细胞的增殖和转移。
2. **标题**：Structural Characterization of SPRY4 and Its Interaction with c-KIT Receptor
**作者**：Wang Y, et al.
**摘要**：利用昆虫细胞系统表达SPRY4重组蛋白，解析其晶体结构，揭示其通过特定结构域与c-KIT受体结合，调节干细胞分化相关的RTK信号传导机制。
3. **标题**：SPRY4 Recombinant Protein Attenuates Fibrosis via Modulating TGF-β Pathway
**作者**：Chen L, et al.
**摘要**：研究证明哺乳动物细胞表达的SPRY4重组蛋白可通过竞争性抑制SMAD蛋白磷酸化，降低TGF-β介导的纤维化反应，为肺纤维化治疗提供潜在策略。
---
注：以上文献为模拟内容，实际研究需通过PubMed/Google Scholar检索关键词(如"SPRY4 recombinant protein"+"functional study")。真实文献可能涉及其在癌症、发育或代谢疾病中的调控机制研究。
**Background of SPRY4 Recombinant Protein**
SPRY4 (SPRY domain-containing protein 4) is a member of the SPRY protein family, characterized by a conserved SPRY domain that mediates protein-protein interactions. This domain, originally identified in *Dictyostelium* signaling proteins, is involved in regulating cellular processes such as proliferation, differentiation, and apoptosis. SPRY4 is encoded by the *SPRY4* gene located on human chromosome 5q31.2 and is widely expressed in tissues, including the brain, kidney, and reproductive organs.
Functionally, SPRY4 acts as a negative regulator of receptor tyrosine kinase (RTK) signaling pathways, particularly the RAS-MAPK cascade. By binding to key components like GRB2 or RAF1. it modulates signal transduction, influencing cell fate decisions during development and tissue homeostasis. Studies link SPRY4 to cancer biology, where it often exhibits tumor-suppressive roles. For instance, epigenetic silencing or downregulation of SPRY4 has been observed in cancers such as colorectal carcinoma and melanoma, correlating with enhanced RAS-MAPK activation and tumor progression.
Recombinant SPRY4 protein is engineered using expression systems (e.g., *E. coli* or mammalian cells*) to produce purified, bioactive forms for research. Its applications span *in vitro* assays to study RTK signaling dynamics, drug discovery targeting hyperactive pathways in cancer, and functional validation of SPRY4 interactions with partners like FBXO11 (an E3 ubiquitin ligase component). Additionally, SPRY4 recombinant protein serves as a tool for antibody development and biomarker studies in diseases linked to dysregulated MAPK signaling.
Recent advances highlight SPRY4's role in non-cancer contexts, including neural development and immune regulation, broadening its therapeutic relevance. However, challenges remain in fully elucidating its tissue-specific functions and post-translational modifications. Overall, SPRY4 recombinant protein is a critical reagent for dissecting cellular signaling mechanisms and exploring targeted therapies.
×
